Both innate and adaptive immunity are crucial for cancer immunosurveillance, but precise therapeutic equations to restore immunosurveillance in cancer patients have yet to be developed. In murine models, α-galactosylceramide (α-GalCer)-loaded, tumor antigen-expressing syngeneic or allogeneic cells can act as cellular adjuvants, linking the innate and adaptive immune systems. In the current study, we established human artificial Research.
Introduction
Numerous studies using irradiated autologous and allogeneic tumor cells, as well as tumor-associated antigen (TAA) proteins, TAA-derived peptides or DNA encoding the TAA have highlighted the therapeutic potential of cancer vaccines (1) (2) (3) . Recently, immunotherapeutic strategies have mostly shifted from use of a single class I TAA peptides to long or multiple peptides or to whole protein antigens in order to stimulate responses to a range of tumor antigen epitopes (4) (5) (6) . Transfection of dendritic cells (DCs) with mRNA encoding TAA induces high levels of antigen protein expression in a reproducible manner, and is available in good manufacturing practice (GMP) grade for use in patients (7, 8) . A crucial regulatory advantage of this mode of immunization is that mRNA transfection does not constitute gene therapy because the mRNA is not integrated into the patient's genome. Furthermore, this approach is not dependent on particular haplotypes as peptides derived from translated proteins are loaded into multiple MHC molecules. DCs transfected with TAA mRNA have already been shown to be effective in generating a robust cytotoxic T lymphocyte (CTL) response and antitumor immunity in both mice (9, 10) and humans (11) (12) (13) . Several groups have attempted to improve MHC class I antigen presentation by administering DCs co-transfected with mRNA encoding TAA and mRNA encoding a variety of potent adjuvants, such as OX40 ligand (14) , GM-CSF (15) or IL-12 (16) . Imiquimod (TLR7) and monophosphoryl lipid A (MPL), a low toxicity LPS-derived TLR-4 agonist derived from salmon (17, 18) . DCs, as "nature's adjuvants", play a pivotal role in determining the character and magnitude of an immune response, and dying tumor cells are known to be selectively taken up by DCs and can be crosspresented to CD8 + T cells. The ex vivo loading of autologous patient DC with tumor specific antigens (ex vivo DC strategy) is one of the most promising current immunotherapeutic strategies (1, 2) . Recently, Sipuleucel-T (Provenge, Dendreon Corp.), an autologous DC vaccine for patients with prostate cancer that uses prostatic acid phosphatase fused with GM-CSF, demonstrated biologic activity and prolonged median survival in Phase III vaccine trials and became the first antigen-specific, cell-based immunotherapy to receive US Food and Drug Administration (FDA) approval (19) . This promising initial outcome with autologous cellular therapy will require long-term follow up, but may herald a new era of prolonged overall cancer survival resulting from tumor antigen-specific T cell responses. On the other hand, ex vivo DC therapy requires the generation of large numbers of DCs from individual patients and the quality of DCs will likely depend on the patient's condition at the time of venipuncture to harvest DC precursors and the cytokine combination used for in vitro DC maturation.
In vivo targeting of DCs has been attempted using chimeras of an anti-DC specific Ctype lectin receptor (CLR) antibody fused to a selected antigen. DEC205 was the first and most studied CLR for antigen targeting purposes, but other DC receptors targeted by cancer vaccines include the mannose receptor (MR), DC-SIGN and CLEC9A (20) (21) (22) (23) .
The efficiency of in vivo DC-targeted therapy depends on the quality of antibodyconjugated antigen and the adjuvant. In the current study, we evaluate another in vivo DC and clinical studies using α-GalCer-loaded DCs, it has been clearly shown that IFN-γ production by iNKT cells correlates with anti-tumor effects (24, 25) . We and others previously reported that α-GalCer behaves as an immunological adjuvant by activating iNKT cells, which in turn induce DC maturation (26, 27) . DCs matured by iNKT cells rapidly express IL-12, resulting in a Th1 polarized immune response. Many studies have demonstrated that co-administration of soluble or cell-associated antigen plus α-GalCer leads to Th1-type CD4 + T cell responses and CTLs. (26) (27) (28) (29) (30) (31) . In developing our immunotherapeutic strategy, we have already shown that α-GalCer-loaded tumor cells or α-GalCer-loaded, ova or trp2 antigen mRNA-transfected allogeneic fibroblasts can efficiently generate antigen-specific CTLs (32, 33) . In these systems, DCs present antigen in vivo in two ways that lead to antitumor effects. The first is cross-presentation of tumorassociated antigen to T cells and the second is presentation of glycolipid to iNKT cells (34, 35) . Important factors for effective generation of CTLs through iNKT cell-licensed host DCs are adequate α-GalCer loading, CD1d expression and the types of vector cells used (35, 36 ).
In the current study, we have further expanded this immunotherapy model to investigate whether mRNA-transfected human vector cells loaded with α-GalCer can 
Materials and Methods

Animals and cell lines
Pathogen-free male beagles were purchased from Kitayama Labs (Nagano, Japan) at 1 year of age and were maintained under specific pathogen-free conditions and studied in compliance with Yamaguchi University institutional guidelines. Pathogen-free C57BL/6 (B6) mice were purchased from CLEA Japan (Tokyo, Japan) at 6-8 weeks of age. iNKT cell-deficient, Jα18
-/-mice were kindly provided by Dr. Taniguchi Murine NIH3T3 cells expressing high levels of murine CD1d (CD1d-NIH3T3) were generated by retrovirus transduction, as previously described (33) .
In vitro transcription (IVT) of RNAs
Research. Enhanced GFP (EGFP) in a pSP64 Poly(A) vector was excised with HindIII and BamHI and re-cloned into the pGEM-4Z vector (Promega, Madison, WI) (33) . The OVA plasmid used for this study was previously described (33) . The expression plasmid for MART-1 (pcDNA3 (+)-MART-1) was isolated in our laboratory (38) . For IVT, these plasmids were linearized by restriction digestion (BamHI for EGFP and OVA and NotI for MART-1), purified by QIAquick PCR Purification Kit (QIAGEN GmbH, Hilden, Germany), and used as a template. The RNAs were generated under a T7 promoter sequence on the vectors by using mMESSAGE mMACHINE T7 Ultra Kit (Ambion, Austin, TX). The template DNAs were then digested with DNase I from the kit. IVT RNAs were then purified by RNeasy Mini/Midi Kits (QIAGEN, Valencia, CA) and eluted in water. RNA integrity was verified by agarose gel electrophoresis under denaturing conditions and the concentration was determined by spectrophotometry.
Preparation of artificial adjuvant vector cells (aAVC)
To load α-GalCer, CD1d-HEK293 cells were cultured for 48 hours in the presence of 500 ng/mL of α-GalCer and then washed three times before transfection. IVT RNAs were transfected into CD1d-HEK293 with TransMessenger transfection kit (QIAGEN) following the manufacturer's instructions. Briefly, the ratio of mRNA, enhancer solution and transmessenger reagent was 1: 2: 4 for performing lipofection. α-GalCer-loaded 
Assays for evaluating in vivo cross-presentation
To prepare the CD1d-HEK293/Gal-ova cells, CD1d-HEK293 transfectants that had been loaded with or without α-GalCer for 2 days were transfected with OVA mRNA. To analyze OVA presentation, mice were adoptively transferred with 2 x 10 6 CFSE-labeled OT-I cells and immunized on the following day with or without 5 x 10 5 CD1d-HEK293/Gal-ova. OT-1 cell proliferation in the spleen was monitored by dilution of CSFE 3 days later. In some experiments, CD11c-DTR mice that had been treated with diphtheria toxin (DT) (Sigma-Aldrich) were used to assess host DC presentation of cellassociated antigens to T cells (39) .
Statistical analysis
Differences in in vitro data were analyzed using Mann-Whitney U-test. P<0.05 was considered statistically significant.
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Results
Optimization of iNKT cell activation by human cell lines transfected with antigenencoding mRNA
We previously showed that even CD1d expressing tumor cells or allogeneic fibroblasts that lack costimulatory molecules were able to present α-GalCer to primary iNKT cells (32, 33, 35) . To develop the human cell therapy system, we screened 11 human fibroblasts and 4 non-fibroblast cell lines for efficacy of mRNA transfection, cell growth, and the capacity to expand iNKT cells after loading with α-GalCer (data not shown) and found that the human embryonic kidney cell line, HEK293, was optimal.
HEK293 cells analyzed by flow-cytometry do not express CD80, CD86 or HLA-DR (data not shown). We could demonstrate stable, high-level expression of human CD1d by the human CD1d HEK293 transfectants (Fig. 1A) , and that CD1d-HEK293 cells loaded with α-GalCer [hereafter referred to artificial adjuvant vector cells, (aAVC) ] could stimulate production of IFN-γ by iNKT cells in vitro (Fig. 1B) . Furthermore, B6 mice injected i.v. with aAVC had more CD1d-dimer + iNKT cells in spleen as compared to untreated mice (Fig. 1C ). In addition, we observed the upregulation of CD25, an activation marker on NKT cells, as well as IFN-γ production by iNKT cells in mice given
CD1d-HEK293/Gal cells but not mice given CD1d-HEK 293 cells (Fig. 1C ).
In the current study, we modified the previous Ribomax (Promega) in vitro transcription protocol (33) by switching to MESSAGE mMACHINE (Ambion), which gives a higher yield of capped polyA + mRNA. High efficiency transfection of EGFP mRNA was observed (Fig. 1D ) and significant amounts of OVA protein were produced in HEK293 and CD1d-HEK293 cells (Fig. 1E) . In quantitative studies, we verified a ten- fold increase in the amounts of OVA protein produced by the transfectants, compared to the previous protocol (data not shown). Importantly, CD1d expression on HEK293 cells did not disturb transfection/expression of OVA mRNA (Fig. 1E ).
In vivo cross-presentation of antigen is dependent on in situ DCs
OT-I cells did not recognize OVA peptide antigen in vitro when it was pulsed on human HEK293 cells, due to the xenogeneic MHC disparity (data not shown). Previously we demonstrated that when transferred intravenously into mice, allogeneic cells loaded with α-GalCer (CD1d hi -NIH3T3/Gal-ova) were mainly captured by splenic CD8 + DCs.
Furthermore, these DCs could cross-present OVA antigen derived from the CD1d hi -NIH3T3/Gal-ova cells in vivo (33) . Therefore, we tested whether human aAVCs-ova were also cross-presented by resident DCs. When CFSE-α-GalCer-loaded, OVA mRNAtransfected aAVC cells (aAVC-ova) were injected into mice, they were captured by in situ splenic CD11c Before applying our system to human studies, we felt it would be important to compare the immunological responses of mice given CD1d-expressing allogeneic vector cells versus syngeneic DCs. To demonstrate the antigen specific T cell response in an allogeneic setting, we used allogeneic murine aAVC (CD1d hi -NIH3T3 cells loaded with α-GalCer and then transfected with ova mRNA, i.e., CD1d-NIH3T3/Gal-ova mRNA) as previously reported (33) . We compared the T cell responses in mice given these murine aAVC to those in mice given DC/Gal transfected with ova mRNA. We found that the T cell response in mice given the aAVC was higher than in mice given DC/mRNA and DC/mRNA/Gal (Fig. 2F) . Also, we verified that an injection of CD1d-NIH3T3-ova alone did not induce DC maturation (data not shown) or T cell responses in vivo (Fig. 2F ). The T cell response in mice given aAVC could not be seen in Jα18 KO mice (Fig. 2G ),
indicating that the T cell response in aAVC-administered mice depends on NKT cells.
Research. (Fig. 3A) . Moreover, the frequency of mature DCs increased in cultures in which both antigen aAVC and iNKT cells were present (Fig. 3B) . On the other hand, we noticed some differences when we assessed the IFN-γ iNKT cell response in each group. By this criterion, iNKT cells were activated only by DC plus CD1d-HEK293/Gal, and very weakly or not at all in other groups (Fig. 3C) . Thus, iNKT cells cannot be fully activated by DCs alone or by DC plus CD1d-HEK293 cells (Fig. 3C ).
aAVCs transfected with mRNA encoding the human melanoma antigen, MART-1 (aAVC-MART1) were prepared, and these aAVCs expressed 18.9r7.4 μg of MART-1 protein/5x10 5 cells as assessed by Western blot (Fig. 4A) . NOG mice lack B, T, NK and iNKT cells and do not reject adoptively transferred human cells. After optimizing the number of imDCs that needed to be transferred into NOG mice, we established a robust system (hDC-NOG) for evaluating the ability of imDCs in situ to phagocytize and present tumor-specific antigen derived from aAVCs to antigen-specific human T cells
Research. (Fig. 4B) . Human imDCs and iNKT cells from HLA-A2 + donors were adoptively transferred into NOG mice with or without aAVC-MART1. Ten hours later, HLA-A2
matched, but otherwise allogeneic JKF6-TILs specific for MART-1 antigen were adoptively transferred into the NOG mice (Fig. 4B) .
CD86 expression by human DCs in NOG mice that received aAVCs and iNKT cells was increased (Fig. 4C) . The antigen presenting activity of the DCs was then evaluated by analyzing CFSE dilution of the transferred HLA-A2 + JKF6-TIL cells by flow cytometry (Fig. 4D ). JKF6-TIL did not proliferate in NOG mice transferred with either TIL plus aAVC or with TIL plus aAVC and imDCs (Fig. 4D, left) , indicating that these T cells could not be stimulated by aAVC alone or by aAVC together with DCs. Significant JKF6-TIL proliferation was only observed in the mixed transfer group (TIL+DC+iNKT+aAVC), suggesting that the human DCs were capable of phagocytosis and cross-presentation to antigen-specific T cells in an HLA-A2 dependent manner (Fig.   4D , right). We interpret these findings to indicate that α-GalCer on aAVCs leads to activation of iNKT cells followed by antigen uptake of the aAVCs by imDCs and presentation by iNKT-licensed mature DCs.
Vaccination with aAVCs results in antigen-specific T cell responses
Next, we evaluated whether tumor antigen-specific T cell responses could be generated in an autologous setting ( with A2-CIR/pep had detectable levels of IFN-γ in the supernatants (Fig. 5B) .
Transduced or non-transduced T cells were then adoptively transferred into NOG mice.
Three hours later syngeneic imDCs were injected i.v. followed 3 hours later by iNKT cells with or without aAVCs (Fig. 5A) . The transferred MART-1 TCR gene-transduced T cells only expanded robustly in the mixed transfer group (CFSE-T+DC+iNKT+aAVCs) (Fig. 5C & 5D ). This proliferation occurred despite the HLA mismatch between aAVC and T cells, suggesting cross-presentation of MART-1 antigen by the human DCs in situ. CD1d-HEK293-MART-1 [aAVC-MART-1(Gal-)] alone was not be enhanced (Fig. 5E ).
In order to evaluate the feasibility of using this system for immunotherapy in patients with low numbers of iNKT cells, we tested PBMCs containing a low number of iNKT cells (iNKT=0.02+/-0.01). For the PBMCs, the frequency of MART-1 TCR genetransduced T cells was kept low (1/1000). In these experiments, proliferation of MART-1-specific T cells occurred in co-cultures containing both DCs and aAVCs more than in cultures with IL-2 alone or IL-2 plus peptide (Fig. 5F, left) . The MART-1-specific T cells maintained their antigen specificity and functioned as cytotoxic T cells as assessed by a flow cytometric CTL assay (Fig. 5F, right) . 
aAVCs activate iNKT cells in vivo in canine models
We next evaluated aAVCs as potetial vaccines in a preclinical safety and adverse event monitoring study using beagles. In these studies, we used 30 Gy-irradiated aAVCs.
Two doses of aAVCs were given to 3 dogs per group; a low dose consisting of 5x10 coculturing PBMCs with 100 ng/mL α-GalCer-loaded murine DCs (42) . Using this approach, we could detect canine iNKT cells and follow their kinetics after the injection of aAVCs (Fig. 6A left and 6B ). The number of iNKT cells increased from day 7 to day 14, but went back to control level one month later (Fig. 6A left and 6B ).
Research. We also evaluated iNKT cell activation in aAVC-treated dogs using an IFN-γ ELISPOT assay (Fig. 6C) (24, 28, 32) . The number of IFN-γ producing cells in aAVCsova immunized dogs increased at 1 week after both the low and high dose aAVC treatment. These data further indicate that aAVCs stimulate iNKT cell proliferation. Most importantly, all dogs in groups receiving both doses of aAVC were monitored from the time of aAVC immunization until 1 to 4 weeks post-immunization and they experienced no adverse effects were noted (Table 1) . We have additionally verified the safety of this therapy in the dog after three injections of aAVCs (data not shown).
Immunization of dogs with aAVC-ova leads to antigen-specific T cell responses
We next tested whether antigen specific T cell immunity can be generated in dogs after immunization with aAVC-ova. Serum was collected from the dogs at different time points after immunization with aAVC-ova, and IL-12 levels were found to be elevated 2 and 6 hours after treatment, suggesting that DC maturation in situ occurs early after aAVC immunization (Fig. 6D) . Fourteen days after an immunization, we restimulated PBMC from immunized dogs with or without OVA protein-transduced canine DCs for 36 hours and measured IFN-γ secretion by ELISPOT. The number of OVA-specific IFN-γ secreting CD8 + T cells was elevated with both doses of aAVCs (Fig. 6E) . Thus, our preclinical study demonstrated that aAVCs could safely and effectively generate an antigen-specific immune response in dogs. 
used repeated injections of aAVC in our studies. To evaluate the antigen-specific T cell response in an allogeneic setting, we used a murine allogeneic system, i.e., allogeneic murine aAVC(CD1d-NIH3T3/Gal-ova mRNA) (33) . We observed an elevated OVA antigen-specific T cell response by boosting with aAVC-ova 2 week after the initial vaccination under the allogeneic setting (data not shown), suggesting that it was not blocked by an allogeneic response by the recipient. Since boosting is very important in any effective immunotherapy strategy, we continue to search optimal conditions to enhance boosting effects. Translational studies using large animals, e.g., dogs or monkeys, serve as an important research intermediary so that discoveries at the bench can ultimately be used in human. Continued development of our aAVC cancer vaccine as an immunotherapeutic
Research. 
required testing in a large animal so that relevant toxicity endpoints could be assessed and efficacy of treatment could be confirmed. The results of a dose-escalation and multipledose design of aAVC delivery to beagles in this study established a robust safety profile for this agent. Furthermore, physical examination, blood chemistry analysis, and autoantibody tests shown in Table 1 , as well as tissue biopsies from liver, lung and other organs from dogs given high dose-aAVCs confirmed the safety of this approach (data not shown).
The biological and immunological systems in dogs and humans share many features, therefore canines trials of immunotherapies provide a significant rationale for continued development of treatment modalities (49) . These various kinds of novel cancer treatments will ultimately become available not only for humans, but also for the treatment of pet dogs. In the current study, we verified the low percentage of iNKT cells in canine PBMCs, however our data showed that canine iNKT cells responded well to human aAVCs. We also found that human PBMC, in which there are only a small number of iNKT cells can respond to aAVC in vitro (data not shown ). We previously demonstrated in a phase I/II study that an increase in IFN-γ producing iNKT cells in PBMCs from lung cancer patients , even in patients with low starting numbers of iNKT cells, was associated with prolonged median survival time (25) . 
